DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Clinical trials for DLBCL ARISING FROM FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL ARISING FROM FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL ARISING FROM FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR-T therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a new type of cell therapy called P-CD19CD20-ALLO1 for people with certain B-cell cancers (like diffuse large B-cell lymphoma) that have come back or not responded to standard treatments. The therapy uses donor immune cells that are specially des…
Matched conditions: DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:00 UTC
-
Could a Pre-Treatment drug make CAR-T work better for tough lymphomas?
Disease control TerminatedThis study tests whether giving a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 participants will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the sa…
Matched conditions: DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 26, 2026 07:59 UTC